Updated:
MedImmune Ventures
AstraZeneca was established in 1998 as a pharmaceutical company headquartered in Cambridge, UK. It develops medicines for cancer and cardiovascular disease...
Overview
AstraZeneca was established in 1998 as a pharmaceutical company headquartered in Cambridge, UK. It develops medicines for cancer and cardiovascular disease and launched Evinova, a HealthTech business.
General information
Firm type
Venture Capital
Year founded
1998
Location
Region
Europe
Country
United States
City
Gaithersburg
Corporate office
One MedImmune Way, Gaithersburg, MD 20878, United States
Principals
Ron Laufer
Senior Managing Director
Edward T. Mathers
Former President
Sector focus
Frequently asked questions
Who runs investment decisions at MedImmune Ventures?
Ron Laufer serves as Senior Managing Director. Edward T. Mathers previously held the role of President and continues to serve on boards of portfolio companies.
How is MedImmune Ventures related to AstraZeneca?
AstraZeneca PLC acts as the sole source of capital through an evergreen structure. The unit functions as an internal corporate venture program rather than a separate fund.
Does MedImmune Ventures participate in fund commitments or only direct deals?
Activity centers on direct investments and co-investments in biotechnology companies. No commitments to external venture funds appear in the record.
What investment stages does MedImmune Ventures typically target?
The program covers seed, start-up, and expansion or late stage rounds within biotechnology and healthcare IT.
Where does the underlying capital come from?
All capital is provided by AstraZeneca PLC as the parent company.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: